Unlocking Early Detection: AI-Powered Breast Cancer Assay in Development
A promising research initiative aims to develop a combined circulating nucleic acid assay to detect early signs of tumor invasion in patients with malignant breast carcinoma. Using next-generation sequencing, the study identifies significantly altered RNA and DNA targets in peripheral blood linked to invasiveness. The developed assay will utilize AI to generate an oncoindicative score, providing a precise measure of cancer risk and progression. This approach leverages circulating RNA markers as non-invasive tools for early detection and monitoring of invasive breast carcinoma, enabling early intervention and personalized treatment strategies.
We are pleased to announce that our BC-monitor, a breast cancer-specific ctDNA diagnostic tool, is now published. This innovative tool effectively detects preclinical metastases and relapses earlier than conventional methods. It identifies evolving mutations in real-time, revealing new pathogenic variants in follow-up plasma samples not found in primary tumors or baseline samples. By monitoring disease progression, this approach enhances treatment strategies, potentially improving therapy effectiveness significantly.
European Life Technologies has officially introduced itself to the Asian market, where our developments in bioinformatics and liquid biopsy have already generated strong professional interest. Our delegation participated in high-level ministerial meetings, engaging in successful discussions with key strategic partners.
